Grifols: Alzheimer treatment shows 'encouraging' results
(CercleFinance.com) - Grifols' combination of human albumin with intravenous immunoglobulin for treating Alzheimer's disease showed "encouraging results" in a clinical trial, the Spanish healthcare company said on Tuesday.
In the study including 496 mild and moderate Alzheimer patients, results showed a statistically significant reduction of 61% in disease progression in both primary efficacy endpoints, cognition and function, Grifols said.
The new results also showed positive effects on the combination of cognition and function, which is very unique in Alzheimer's investigation, the group said.
Another indicator - assessing memory, orientation, judgment, community affairs, home and hobbies, and personal care - showed a statistically significant 71% less decline with respect to placebo, it said.
The shares of Grifols were up 2.6% on the news in Madrid.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In the study including 496 mild and moderate Alzheimer patients, results showed a statistically significant reduction of 61% in disease progression in both primary efficacy endpoints, cognition and function, Grifols said.
The new results also showed positive effects on the combination of cognition and function, which is very unique in Alzheimer's investigation, the group said.
Another indicator - assessing memory, orientation, judgment, community affairs, home and hobbies, and personal care - showed a statistically significant 71% less decline with respect to placebo, it said.
The shares of Grifols were up 2.6% on the news in Madrid.
Copyright (c) 2019 CercleFinance.com. All rights reserved.